COMPANY PROFILE
M2BIO SCIENCES INC.
SYMBOL : WUHN
SECTOR : PSYCH.
O/S : 48 M
MARKET CAP : $ 15 M
MARKET OPPORTUNITY : UP TO $350 B
M2BIO SCIENCES INC. is the MOST UNDERVALUED company in the psychedelic market being one of the only companies in the world to have already carried out an in vitro / in vivo study with psilocybin in animals.
Psilocybin Study with University Of Pretoria, South Africa
M2BIO SCIENCES INC. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands.
In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies
MAJOR DEVELOPMENT
M2BIO SCIENCES INC. is currently in Pre-enrolment Patient- screening for Phase 1 Human trial in Psilocybin research for medical conditions such as alcohol addiction and related mental health diseases & cardiovascular conditions.
COMPANY BRIEF
| Researching and developing indications for psilocybin new therapies
| Researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands
| Currently in Pre-enrolment Patient- screening for Phase 1 Human trial.
| Cosmetics and FSMP company with cannabinoid and psilocybin research, formulation and delivery system divisions
HIGHLIGHTS
| First in market to research psilocybin for treatment of alcoholism and cardiovascular tissue
| Established distribution channels in the US, Canada, Europe and Africa
| Early stage entry into cannabinoid and psilocybin company- Enormous upside
| Research undiscovered properties of cannabinoids for treatment of respiratory infectious diseases
M2BIO DEVELOPMENT
M2Bio ACQUISITIONS, DIVISIONS & STRATEGIC PARTNERS
WUHAN Cosmetics and food name Dr. AnnaRx
WUHAN infused beverages MEDSPRESSO CBD
WUHAN infused beverages MEDSPRESSO Mushroom
VERY SMALL FLOAT
M2BIO SCIENCES INC. O/S is ONLY 48 millions with a small float of 10 millions
M2Bio COMPARABLE
RVV | OTC
COMPANY INFORMATION
JOIN FACEBOOK INVESTOR GROUP
Wuhan last news | article
Psychedelic highlights | October 05 – 09
Psychedelic highlights | October 05 – 09 1. M2Bio Sciences, Inc | WUHN Announce a new Chief Operating Officer M2Bio Sciences Inc announce past monday the appointment of Mr. Willem…
A new Chief Operating Officer for M2Bio Science inc | WUHN
CAPE TOWN, SA / ACCESSWIRE / October 5, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research…
Investors: If you like Compass Pathways you will love M2Bio Sciences.
For several weeks now, no one can dispute that the psychedelics market is one of the hottest. Several IPOs since spring (MMED, NUMI, TRIP …) have taken the market to…
Psychedelic highlights | September 21 – 25
Psychedelic highlights | September 21 – 25 1. COMPASS Pathways | CMPS can’t be stopped and has reached new heights this week. Compass Pathways continues its strong growth following its…
M2Bio Sciences | WUHN enters cannabis production and projects nearly $10M (us) in revenue for the first year
M2Bio Sciences, Inc | WUHN on OTC Earlier this week, M2Bio Sciences Inc | WUHN, which is already involved in research and development for psilocybin new therapies that will help patients who…
Wuhan General Group Corporate Update on Tsime Pharmaceuticals Acquisition
CAPE TOWN, SA / ACCESSWIRE / September 22, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is…
Psychedelic highlights | Sept. 14 – 18
Psychedelic highlights | September 14 – 18 1. COMPASS Pathways | CMPS enter the market with a value of 1.2 billion and announces pricing of upsized initial public offering Compass…
Psychedelic highlights | August 31 – 04
Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most…
M2Bio Sciences | An opportunity in the psychedelic and cannabinoids market
M2Bio Sciences, Inc | WUHN on OTC Who are M2Bio Sciences ? M2Bio Sciences | WUHN through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes…
The psychedelics market, still some bargains ?
According to Cannacord’s most recent report on the psychedelics market, the value of the market is more than $100 billion. Some companies are approaching billions of dollars (CAD) in valuation.…
Wuhan General Group Corporate Update | WUHN (OTC)
M2Bio Sciences, Inc | WUHN on OTC (Wuhan General Group) CAPE TOWN, SA / ACCESSWIRE / August 21, 2020 / WUHAN GENERAL GROUP, INC. (OTC Pink:WUHN) (“Wuhan” or the “Company”), a bioceutical…
Why M2Bio Sciences | WUHN is a stock to watch ?
M2Bio Sciences, Inc | WUHN on OTC (Formely Wuhan General Group) For several weeks now, a penny stock has started opening the eyes of investors and it is not over.…